Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Biophytis
- Target Recruit Count
- 238
- Registration Number
- NCT04472728
- Locations
- 🇺🇸
Abrazo Health, Phoenix, Arizona, United States
🇺🇸University of California, Irvine, Irvine, California, United States
🇺🇸Barnum Medical Research, Inc. 1029 Keyser Ave Suite H, Natchitoches, Louisiana, United States
A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)
- Conditions
- SarcopeniaGait Disorders in Old AgeMuscle Weakness
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Biophytis
- Target Recruit Count
- 233
- Registration Number
- NCT03452488
- Locations
- 🇺🇸
Advanced Clinical Research, West Jordan, Utah, United States
🇺🇸SC Clinical Research, Inc, Garden Grove, California, United States
🇺🇸California Research Foundation, San Diego, California, United States
An OBServational Clinical Trial (SARA-OBS) in Sarcopenia and Sarcopenic Obesity in Patients Aged 65 Years and Over
- Conditions
- Muscle WeaknessSarcopeniaGait Disorders in Old Age
- First Posted Date
- 2017-01-16
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Biophytis
- Target Recruit Count
- 218
- Registration Number
- NCT03021798
- Locations
- 🇺🇸
Institut On Aging, Gainesville, Florida, United States
🇺🇸Jean Mayer USDA Human Nutrition research Center on Aging Tufts University, Boston, Massachusetts, United States
🇺🇸Columbia University New York, New York, New York, United States
News
Sarcopenia Pipeline Shows Robust Growth with 18+ Pharma Companies Developing Novel Therapies
• The sarcopenia market remains largely untapped with no approved drug therapies in major markets, despite significant unmet medical needs in an aging global population. • DelveInsight reports 18+ pharmaceutical companies actively developing 20+ pipeline drugs for sarcopenia, with promising candidates including Biophytis' BIO101, TNF Pharmaceuticals' MYMD-1, and Epirium Bio's MF-300. • Recent regulatory milestones include Fast Track Designation for Lipocine's LPCN1148 for sarcopenia in patients with decompensated cirrhosis, signaling increased recognition of sarcopenia as a distinct clinical condition.
Biophytis Reports Promising Results: BIO101 and GLP-1 Combination Restores Muscle Strength in Obesity
New preclinical data shows that combining BIO101 with GLP-1 receptor agonists significantly improved mobility and grip strength in diet-induced obese mice, addressing a critical gap in obesity treatment.
Novavax Launches Clinical Trial for JN.1 Subvariant COVID-19 Vaccine
Novavax initiates a new clinical trial to evaluate the safety and immunogenicity of its JN.1 subvariant vaccine (NVX CoV2705) with Matrix-M adjuvant. The study will compare results with the previously authorized NVX-CoV2601 vaccine, marking a significant step in addressing emerging COVID-19 variants.
Biophytis Presents BIO101 Obesity Program Data at SCWD International Congress, Plans Phase 2 Trial
Biophytis presented its OBA program featuring BIO101 (20-hydroxyecdysone) at the 17th SCWD International Congress, highlighting its potential to mitigate muscle loss induced by GLP-1RA therapies in obese patients.